A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007). - Wikidata - wikimedia - TriplyDB

A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007).

A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007).

http://www.wikidata.org/entity/Q34661892

about

Rectal pre-exposure prophylaxis (PrEP)Mucosal effects of tenofovir 1% gel Exploring the feasibility of multi-site flow cytometric processing of gut associated lymphoid tissue with centralized data analysis for multi-site clinical trials The Safety of Multiple Flexible Sigmoidoscopies with Mucosal Biopsies in Healthy Clinical Trial Participants.Adherence to rectal gel use among mainly ethnic minority young men who have sex with men during a 3-month placebo gel trial: implications for microbicide research.Topical microbicides and HIV prevention in the female genital tract Use of a novel technology to track adherence to product use in a microbicide trial of short duration (MTN-007)Commercial lubricant use among HIV-negative men who have sex with men in Los Angeles: implications for the development of rectal microbicides for HIV prevention Order of orifices: sequence of condom use and ejaculation by orifice during anal intercourse among women: implications for HIV transmission Use of human mucosal tissue to study HIV-1 pathogenesis and evaluate HIV-1 prevention modalities.Rectal microbicide development.Rectal-specific microbicide applicator: evaluation and comparison with a vaginal applicator used rectally.Reduced immune activation during tenofovir-emtricitabine therapy in HIV-negative individuals.T lymphocyte density and distribution in human colorectal mucosa, and inefficiency of current cell isolation protocols.A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).The rational design and development of a dual chamber vaginal/rectal microbicide gel formulation for HIV prevention.A new hypothesis on HIV cure.Project Gel a Randomized Rectal Microbicide Safety and Acceptability Study in Young Men and Transgender Women.A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection A Phase 1 Randomized, Blinded Comparison of the Pharmacokinetics and Colonic Distribution of Three Candidate Rectal Microbicide Formulations of Tenofovir 1% Gel with Simulated Unprotected Sex (CHARM-02).Investigational reverse transcriptase inhibitors for the treatment of HIV.Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir.Safety and efficacy of tenofovir/IQP-0528 combination gels - a dual compartment microbicide for HIV-1 prevention Influence of Partner Type on Acceptability and Likelihood of Use of a Rectal Microbicide Among Young Men Who Have Sex With Men in the United States and Puerto Rico.Broadly Neutralizing Anti-HIV Antibodies Prevent HIV Infection of Mucosal Tissue Ex Vivo Successes and challenges of HIV prevention in men who have sex with men Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment.Non-Antiretroviral Microbicides for HIV Prevention.Rectal 1% Tenofovir Gel Use Associates with Altered Epidermal Protein Expression.Vaginally delivered tenofovir disoproxil fumarate provides greater protection than tenofovir against genital herpes in a murine model of efficacy and safety.Methodological lessons from clinical trials and the future of microbicide research.The development of rectal microbicides for HIV prevention.An overview of antiretroviral pre-exposure prophylaxis of HIV infection."Like Holding an Umbrella Before It Rains": Acceptability of Future Rectal Microbicides Among Men Who Have Sex With Men in India-A Modified Technology Acceptance Model.MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel.Drug transporter gene expression in human colorectal tissue and cell lines: modulation with antiretrovirals for microbicide optimization.Using conjoint analysis to determine the impact of product and user characteristics on acceptability of rectal microbicides for HIV prevention among Peruvian men who have sex with men.On-demand microbicide products: design matters.Rectal Douching Among Men Who Have Sex with Men in Paris: Implications for HIV/STI Risk Behaviors and Rectal Microbicide Development.A novel preventive strategy against HIV-1 infection: combinatorial use of inhibitors targeting the nucleocapsid and fusion proteins.

P2860

Q26829713-5A665797-A96F-46CF-9BDB-39AEBC67F1DF Q28545969-5DA60B33-7211-4542-9505-C3C994925E07 Q30958546-F47BB152-7E02-45DE-8302-334C18CE3EB0 Q33470044-E4B5EE87-5724-44F1-844E-D786D337557A Q34022053-16250A8D-5F6F-4A37-97ED-49316019CFC8 Q34086820-F6C78C2F-983C-40A5-8A19-1670CD02A910 Q34149653-DBA43D46-A1C8-462E-AC7E-226FE5A4B9F6 Q34302073-4631B527-6E39-4ED8-B1CD-8FD8607BCD66 Q34440636-BFAE1A72-8C06-4F87-87FD-9889DA07430F Q34566597-A87E089F-17C7-4E0A-8102-CC69034D5B48 Q34575590-D760E99A-8085-41D6-AD3A-5C8C454BDB9C Q35061678-0E03B84A-CD23-4896-8F41-493A2D735AF7 Q35174468-2FEA610D-D471-4F94-B19F-79F6D92F18B9 Q35344900-57F37CFA-06F8-4FC6-A88C-1AE1DB9FB11A Q35571216-767210DE-90CF-40CC-91F1-F81622471B1D Q35822713-D9CB436D-878C-4DA8-AE61-C5E7D727D59B Q36028475-D0B7942D-7D61-4876-8A8E-CF4B7D0897D0 Q36065036-73C764BF-E8D7-4415-8D25-788E1FCC52F2 Q36286901-C2CD5810-E7F8-48EC-B62D-D47D280E9B1B Q36294792-7D2B3491-2B81-472B-AE5C-FB37FA02380E Q36306231-5663CD11-2494-454E-AAAB-93A9AE10A04C Q36306935-5532D77C-F71F-48F3-9585-B99C78EB608B Q36409617-5C3CD078-50A1-4710-B001-9A0A386C94D1 Q36421478-9E86C3A7-8A90-4B62-9C11-032D90327E20 Q36571900-4AFA38DA-6EEA-4C7C-BA37-84EB432802A6 Q36897630-641EFCD8-0EDC-4F0C-B949-0DFABE824169 Q37102101-222CF145-FEB5-4F6E-9CA3-B4416B3CAE17 Q37317845-A54ACCC3-CC10-4EA6-A0DA-24C616061CCF Q37346055-4687BE53-6FC5-445C-9CBD-BD59B5C9C37D Q37544735-0BE7D104-003C-4714-B5F7-3D8ABEC63B77 Q38062882-5451BF95-21AD-475E-BABE-272605C26E4C Q38165222-234C5646-026C-4E55-9D13-F4B271F6536A Q38196410-0932A88B-82ED-47CA-9B71-EA2848E36C78 Q38662018-28CE7C18-B1CF-4190-8444-AF530ADDFD8E Q38781682-529E239A-5186-4141-B97D-744472CA7ABD Q38823939-65A0E267-23F6-4E36-A546-95B57B01D583 Q38942170-77D778A0-E08F-4300-BB30-E72EA133631B Q39356290-8D1BF834-1F7D-49A8-9142-D91AFC22CA38 Q40098588-D87012FA-4B5B-434D-A55A-5B65AA641897 Q40170253-432C5791-DD40-47D4-9D45-44A422417A48

P2860

A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007).

http://www.wikidata.org/entity/Q34661892

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

A phase 1 randomized, double b ...... of tenofovir 1% gel (MTN-007).

@ast

A phase 1 randomized, double b ...... of tenofovir 1% gel (MTN-007).

@en

A phase 1 randomized, double b ...... of tenofovir 1% gel (MTN-007).

@nl

type

label

A phase 1 randomized, double b ...... of tenofovir 1% gel (MTN-007).

@ast

A phase 1 randomized, double b ...... of tenofovir 1% gel (MTN-007).

@en

A phase 1 randomized, double b ...... of tenofovir 1% gel (MTN-007).

@nl

prefLabel

A phase 1 randomized, double b ...... of tenofovir 1% gel (MTN-007).

@ast

A phase 1 randomized, double b ...... of tenofovir 1% gel (MTN-007).

@en

A phase 1 randomized, double b ...... of tenofovir 1% gel (MTN-007).

@nl

P1433

Q34661892-47CDA75A-BA6B-40F1-863F-240A431C09EE

P1476

Q34661892-E2579A2B-6DED-4AAC-B618-7777FD0BE97F

P2093

Q34661892-03B2BA7E-A4CE-4E66-A00A-FA152925DCAC

Q34661892-119CCC58-E92E-4EB2-BEC3-E6FF435AAF1F

Q34661892-51594562-B321-42E0-BE50-EAA3F3D7B00A

Q34661892-5B4A8320-357B-4B79-9DE1-B8AA7B73D124

Q34661892-7151D139-F5C4-4036-B9E0-19DBF0C4DA85

Q34661892-9F28049D-FC03-4122-B0D2-46AC1D5B3389

Q34661892-CB00B2E6-AB79-4FA6-8214-3B5245724D89

Q34661892-EC1ECBCC-5E50-4934-A97A-8CBEAA0FD2E4

Q34661892-FABBFB14-61C8-4EA4-876B-4B33DB0418C2

P2860

Q34661892-0550997E-CB42-4FC2-AF91-785434E256C8

Q34661892-2656CC6E-3AED-4736-A7E0-945681586003

Q34661892-447A097F-B216-4237-AC71-1A7CFE0C9AA8

Q34661892-4C489A0E-84AD-4505-89D3-B7D76AC56F30

Q34661892-73D8BBCC-BA90-4B14-A431-83A8E53360C3

Q34661892-76B61025-B83B-4946-B096-CDF780DEF096

Q34661892-83023728-FC0A-4E29-B428-62DE656323D8

Q34661892-87C9FB39-5DF9-495A-A9CD-53D1FA37D1FF

Q34661892-8AF8EF9D-BD6C-4599-8E8B-7A795FC50A87

Q34661892-8B8F2861-ECF9-45F1-8AE1-6217ADA9204D

P304

Q34661892-F2402BF6-D830-45CD-980A-BF3D7D70A2EE

P31

Q34661892-483EC838-9C39-4881-ABA7-790791BE2C2B

P356

Q34661892-92F09EAE-549E-4106-9B7A-678C6C63C207

P407

Q34661892-D438AFDE-931A-487D-9FAD-5CDEB9A82778

P433

Q34661892-1F7A589A-246F-454E-9D4A-B39728A527F6

P478

Q34661892-DCA28E45-0EEB-4B1B-9D09-D3C1BC55CD2E

P50

Q34661892-1B6E54D2-0AE8-4C2D-8F00-ECFCB3978234

Q34661892-4133615A-35AC-42A5-80B0-D67C189BFDBF

P577

Q34661892-5353B1D2-975A-4BBE-B00F-3DD835787212

P5875

Q34661892-F18A9ADA-C913-4610-A192-2FA73FB0BF51

P698

Q34661892-4E531E3D-62CD-4BA8-B964-CE30A7956420

P921

Q34661892-F1247922-8B36-4EC3-9B95-479CDCCD6455

P932

Q34661892-B828E8C6-3433-4BC5-8B82-4332C6523BD2

P356

JOURNAL.PONE.0060147

P1433

P1476

A phase 1 randomized, double b ...... of tenofovir 1% gel (MTN-007).

@en

P2093

Alex Carballo-Dieguez

http://www.w3.org/2001/XMLSchema#string

Craig Hoesley

http://www.w3.org/2001/XMLSchema#string

Ian McGowan

http://www.w3.org/2001/XMLSchema#string

James Y Dai

http://www.w3.org/2001/XMLSchema#string

Jeanna Piper

http://www.w3.org/2001/XMLSchema#string

Ken Mayer

http://www.w3.org/2001/XMLSchema#string

Laura Janocko

http://www.w3.org/2001/XMLSchema#string

Philip Andrew

http://www.w3.org/2001/XMLSchema#string

Ratiya Kunjara Na Ayudhya

http://www.w3.org/2001/XMLSchema#string

P2860

First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy

Elevated risk for HIV infection among men who have sex with men in low- and middle-income countries 2000-2006: a systematic review

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

Heterosexual anal intercourse among community and clinical settings in Cape Town, South Africa.

A summary of preclinical topical microbicide rectal safety and efficacy evaluations in a pigtailed macaque model.

Rectal microbicides: can we make them and will people use them?

Optimization of media for detection of hydrogen peroxide production by Lactobacillus species.

Reformulated tenofovir gel for use as a dual compartment microbicide.

P304

e60147

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0060147

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Ross D Cranston

P577

2013-04-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236189855

http://www.w3.org/2001/XMLSchema#string

P698

23573238

http://www.w3.org/2001/XMLSchema#string

P921

P932

3616022

http://www.w3.org/2001/XMLSchema#string